• Follow Essays, Opinions and Curated News for the Health Economics, Finance & Business Management Space on WordPress.com
  • Member Statistics

    • 711,670 Colleagues-to-Date [Sponsored by a generous R&D grant from iMBA, Inc.]
  • Our ME-P Channels

  • ME-P Archives Silo [2006 – 2018]


    New "Self-Directed" Study Option SinceJanuary 1st, 2017
  • Dr. David Marcinko [Publisher Emeritus]


    As a Distinguished University Professor and Endowed Department Chairman, Dr. David Edward Marcinko MBBS DPM MBA MEd BSc CMP® was a NYSE broker and investment banker for a decade who was respected for his unique perspectives, balanced contrarian thinking and measured judgment to influence key decision makers in strategic education, health economics, finance, investing and public policy management.

    Dr. Marcinko is originally from Loyola University MD, Temple University in Philadelphia and the Milton S. Hershey Medical Center in PA; Oglethorpe University and Atlanta Hospital & Medical Center in GA; and Aachen City University Hospital, Koln-Germany. He is one of the most innovative global thought leaders in health care entrepreneurship today.

    Professor Marcinko was a board certified physician, surgical fellow, hospital medical staff Vice President, public and population health advocate, and Chief Executive & Education Officer with more than 425 published papers; 5,150 op-ed pieces and over 135+ domestic / international presentations to his credit; including the top ten [10] biggest pharmaceutical companies and financial services firms in the nation. He is also a best-selling Amazon author with 30 published text books in four languages [National Institute of Health, Library of Congress and Library of Medicine].

    Dr. Marcinko is past Editor-in-Chief of the prestigious “Journal of Health Care Finance”, and a former Certified Financial Planner® who was named “Health Economist of the Year” in 2010, by PM magazine. He is a Federal and State court approved expert witness featured in hundreds of peer reviewed medical, business, economics and trade publications [AMA, ADA, APMA, AAOS, Physicians Practice, Investment Advisor, Physician’s Money Digest and MD News] etc.

    As a licensed insurance agent, RIA – SEC registered representative, Marcinko was Founding Dean of the fiduciary and niche focused CERTIFIED MEDICAL PLANNER® online chartered designation education program; as well as Chief Editor of the HEALTH DICTIONARY SERIES® Wiki Project.

    Dr. Marcinko’s professional memberships included: ASHE, AHIMA, ACHE, ACME, ACPE, MGMA, FMMA and HIMSS. He was a MSFT Beta tester, Google Scholar, “H” Index favorite and one of LinkedIn’s “Top Cited Voices”. Presently, Marcinko is “ex-officio” and R&D Scholar-on-Sabbatical for iMBA, Inc.



  • PodiatryPrep.org

    Lower Extremity Trauma
    [Click on Image to Enlarge]

  • Most Recent ME-Ps

  • ME-P Free Adverting Sales Consultation

    The “Medical Executive-Post” is about connecting doctors, health care executives and modern consulting advisors. It’s about free-enterprise, business, practice, policy, personal financial planning and wealth building capitalism. We have an attitude that’s independent, outspoken, intelligent and so Next-Gen; often edgy, usually controversial. And, our consultants “got fly”, just like U. Read it! Write it! Post it! “Medical Executive-Post”. Call or email us for your FREE advertising and sales consultation TODAY [770.448.0769]

    Product Details

    Product Details

  • Medical & Surgical e-Consent Forms

  • Hope Hetico RN MS [Managing Editor]

    Prof. Hetico





    USNews.com, Reuters.com,
    News Alloy.com,
    and Congress.org

    Comprehensive Financial Planning Strategies for Doctors and Advisors: Best Practices from Leading Consultants and Certified Medical Planners(TM)

    Product Details

    Product Details

    Product Details

  • iMBA White Papers

    Customized Industry Topics [$1,500 unlimited corporate license]October 1st, 2017
    Medical Clinic Valuations * Endowment Fund Management * Health Capital Formation * Investment Policy Statement Analysis * Provider Contracting & Negotiations * Marketplace Competition * Revenue Cycle Enhancements; and more! HEALTHCARE FINANCIAL INDUSTRIAL COMPLEX
  • Ann Miller RN MHA [Executive-Director]

    iMBA VIRTUAL OFFICES [1.770.448.0769] Atlanta, GA.
    Location doesn't matter. We welcome new long-distance clients and colleagues.

  • ME-P Publishing


    If you want the opportunity to work with leading health care industry insiders, innovators and watchers, the “ME-P” may be right for you? We are unbiased and operate at the nexus of theoretical and applied R&D. Collaborate with us and you’ll put your brand in front of a smart & tightly focused demographic; one at the forefront of our emerging healthcare free marketplace of informed and professional “movers and shakers.” Our Ad Rate Card is available upon request [770-448-0769].

  • Reader Comments, Quips, Opinions, News & Updates

  • Start-Up Advice for Businesses, DRs and Entrepreneurs

    ImageProxy “Providing Management, Financial and Business Solutions for Modernity”
  • Up-Trending ME-Ps

  • Capitalism and Free Enterprise Advocacy

    Whether you’re a mature CXO, physician or start-up entrepreneur in need of management, financial, HR or business planning information on free markets and competition, the "Medical Executive-Post” is the online place to meet for Capitalism 2.0 collaboration. Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds. ******************************************************************** THE ME-P DISCLAIMER: Posts, comments and all opinions do not necessarily represent iMBA, Inc.
  • OIG Fraud Warnings

    Beware of health insurance marketplace scams OIG's Most Wanted Fugitives at oig.hhs.gov

The Pharmaceutical Industry

Join Our Mailing List

Prognosis for Big Pharma

[By Staff Writers]

According to the Wall Street Journal, generic drug competition is expected to wipe $67 billion from top pharmaceutical companies’ annual U.S. sales between 2007 and 2012.

Why? More than three dozen drugs lose patent protection; roughly half of the companies’ combined 2007 U.S. sales.  

Moreover, during the five years from 2002 through 2006, the industry brought to market 43 percent fewer new chemical-based drugs than in the last five years of the 1990s, despite doubling R&D spending. 


And so, what do you think about this grim prognosis for big pharma as patents expire and the industry is failing to find new drugs to replace existing ones?

Product DetailsProduct DetailsProduct Details



3 Responses

  1. A New Drug Pricing Report

    Did you know that according to Delta Marketing Dynamics, the nation’s pharmaceutical companies increased wholesale prices for the 50 top-selling branded drugs by an average of 7.82 percent in 2007? And, similar increases of 6.73 percent and 6.22 percent were noted in the previous two years that were almost double the overall U.S. economy’s 4.1 percent annual inflation rate.

    Some individual drugs even had double-digit price increases over three years. For example:

    • GlaxoSmithKline PLC raised the price of antidepressant Wellbutrin XL by 44.5 % from 2005-07;
    • Sanofi-Aventis SA raised the price of sleep drug Ambien 70.1 percent;
    • Shire PLC increased the price of attention-deficit disorder medication, Adderall XR, by 33.5%;
    • Cholesterol fighting Lipitor-the world’s top selling drug that made $13 billion in 2007 for Pfizer Inc-rose 16 %.

    The report was published in the Wall Street Journal.


  2. Pharma Companies Spent $148,047,760 on Lobbying in 2015

    The LA Times recently released an article on healthcare industry political lobbying. Here are some key findings from the report:

    • Pharmaceutical manufacturing spent $148,047,760 on lobbying in 2015.
    • Hospitals and nursing homes spent $93,592,884 on lobbying in 2015.
    • Health professionals (including physician groups) spent $89,928,202.
    • Health services/insurers/HMOs spent $74,356,196 on lobbying in 2015.
    • In 2016 pharmaceutical companies contributed over $17 million to campaigns.
    • The top recipient of industry money was Paul Ryan who received $230,000+

    LA Times, November 15, 2016


  3. Janssen Spent $7 Billion on Research and Development in 2016

    Janssen recently released a price transparency report for 2016. Here are some key findings from the report:

    • Janssen spent $7 billion on research and development in 2016.
    • The average list price change of Janssen pharmaceuticals was 8.5%.
    • The average net price change of Janssen pharmaceutical products was 3.5%.
    • Janssen offered $11 billion dollars in total rebates and discounts in 2016.
    • 870,000 commercially insured patients used the Janssen CarePath Savings Program.
    • Janssen spent $4.5 billion on global pharmaceutical marketing and sales.

    Source: Janssen, February 27, 2017



Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: